Analyzing Collegium Pharmaceutical (COLL) and Its Competitors

Collegium Pharmaceutical (NASDAQ:COLL) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Collegium Pharmaceutical to similar companies based on the strength of its valuation, institutional ownership, profitability, dividends, earnings, risk and analyst recommendations.

Risk & Volatility

Collegium Pharmaceutical has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical’s peers have a beta of -3.71, indicating that their average stock price is 471% less volatile than the S&P 500.

Profitability

This table compares Collegium Pharmaceutical and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	5.93%	91.43%	15.57%
Collegium Pharmaceutical Competitors	-2,381.29%	-218.58%	-15.77%

Insider & Institutional Ownership

32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 1.9% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Collegium Pharmaceutical and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57 million	$62.87 million	19.69
Collegium Pharmaceutical Competitors	$5.42 billion	$3.22 billion	550.77

Collegium Pharmaceutical’s peers have higher revenue and earnings than Collegium Pharmaceutical. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations for Collegium Pharmaceutical and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	1	1	7	1	2.80
Collegium Pharmaceutical Competitors	7782	13874	25765	1035	2.41

Collegium Pharmaceutical presently has a consensus price target of $44.88, suggesting a potential upside of 83.79%. As a group, “Pharmaceuticals” companies have a potential upside of 26.03%. Given Collegium Pharmaceutical’s stronger consensus rating and higher possible upside, research analysts plainly believe Collegium Pharmaceutical is more favorable than its peers.

Summary

Collegium Pharmaceutical beats its peers on 8 of the 13 factors compared.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.